Comment on

• Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.

  Quénet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, Facy O, Arvieux C, Lorimier G, Pezet D, Marchal F, Loi V, Meeus P, Juzyna B, de Forges H, Paineau J, Glehen O; UNICANCER-GI Group and BIG Renape Group. Quénet F, et al. Lancet Oncol. 2021 Feb;22(2):256-266. doi: 10.1016/S1470-2045(20)30599-4. Epub 2021 Jan 18. Lancet Oncol. 2021. PMID: 33476595 Clinical Trial.
• Limitations of the PRODIGE 7 trial.

  Rovers KP, Kok NFM, Punt CJA, Tanis PJ, de Hingh IHJT. Rovers KP, et al. Lancet Oncol. 2021 May;22(5):e174. doi: 10.1016/S1470-2045(21)00063-2. Lancet Oncol. 2021. PMID: 33932372 No abstract available.
• Limitations of the PRODIGE 7 trial.

  Bhatt A, Mehta S, Kammar P, Saklani A. Bhatt A, et al. Lancet Oncol. 2021 May;22(5):e175. doi: 10.1016/S1470-2045(21)00062-0. Lancet Oncol. 2021. PMID: 33932373 No abstract available.
• Limitations of the PRODIGE 7 trial.

  Carboni F, Valle M. Carboni F, et al. Lancet Oncol. 2021 May;22(5):e176. doi: 10.1016/S1470-2045(21)00088-7. Lancet Oncol. 2021. PMID: 33932374 No abstract available.
• Limitations of the PRODIGE 7 trial.

  Cashin P. Cashin P. Lancet Oncol. 2021 May;22(5):e177. doi: 10.1016/S1470-2045(21)00096-6. Lancet Oncol. 2021. PMID: 33932375 No abstract available.
• Limitations of the PRODIGE 7 trial.

  Ströhlein MA, Heiss MM. Ströhlein MA, et al. Lancet Oncol. 2021 May;22(5):e178. doi: 10.1016/S1470-2045(21)00134-0. Lancet Oncol. 2021. PMID: 33932376 No abstract available.